On one hand, activation of genes under the control IRF-3, leads mostly to the production of type I Interferons that are generally accepted as acting anti-cancer agents (108), while NF-κB activation promotes the production of cytokines that are mostly considered pro-tumorigenic, such as IL-6 (109, 110). The gene discussed is IL6; the disease is cancer.